1. A 66-year-old woman with hypertension and heart failure with reduced ejection fraction (HFrEF) presents to the emergency department with two hours of progressive tongue and lip swelling. She has no urticaria, no pruritus, and no prior allergic reactions. Her medications include lisinopril 10 mg daily (started 14 months ago), carvedilol, and furosemide. Her airway is assessed as patent but her tongue occupies most of the oral cavity. Epinephrine 0.3 mg intramuscularly and diphenhydramine 50 mg intravenously are administered without improvement over 40 minutes. Which of the following correctly identifies the diagnosis, its mechanistic basis, and the most appropriate next pharmacological intervention?
A) This is anaphylactic angioedema from IgE-mediated sensitization to lisinopril developing after 14 months of exposure; the failure of epinephrine indicates the patient requires high-dose intravenous corticosteroids and repeat epinephrine at 0.5 mg to overcome the established IgE-mediated mast cell activation
B) This is hereditary angioedema (HAE) triggered by lisinopril use, caused by C1-esterase inhibitor deficiency that was unmasked by ACEi-induced bradykinin accumulation; C1-esterase inhibitor concentrate should be administered intravenously as definitive treatment for this complement-deficient state
C) This is ACEi-induced bradykinin-mediated angioedema; the failure of epinephrine and diphenhydramine is expected because histamine is not the mediator — bradykinin acting on vascular endothelial B2 receptors drives the increased permeability; lisinopril must be permanently discontinued and icatibant 30 mg subcutaneously (a competitive B2 receptor antagonist) administered to directly block the bradykinin-driven permeability increase, with fresh frozen plasma as an alternative if icatibant is unavailable
D) This is ACEi-induced angioedema from excessive angiotensin II accumulation proximal to the lisinopril block; the correct intervention is to administer an ARB (angiotensin receptor blocker) intravenously to block the accumulated angiotensin II at AT1 receptors on vascular endothelium and reverse the permeability increase
E) This is bradykinin-mediated angioedema confirmed by the failure of epinephrine; the correct management is to continue lisinopril at half the current dose because complete discontinuation will cause rebound angiotensin II surges that worsen the permeability increase, and to administer tranexamic acid intravenously to inhibit the kallikrein-kinin cascade responsible for bradykinin generation
ANSWER: C
Rationale:
The clinical presentation — non-pruritic, non-urticarial angioedema of the tongue and lips in a patient on a long-term ACE inhibitor, with failure of epinephrine and diphenhydramine — is diagnostic of ACEi-induced bradykinin-mediated angioedema; ACE (kininase II) is one of the two principal enzymes degrading bradykinin, and lisinopril's inhibition of ACE allows bradykinin to accumulate in tissues including the oropharyngeal mucosa; accumulated bradykinin activates B2 receptors on vascular endothelial cells, increasing vascular permeability and producing the characteristic non-pitting, non-pruritic, urticaria-free edema; because histamine is not the mediator, antihistamines (diphenhydramine) and corticosteroids are ineffective, and epinephrine provides at most transient vasoconstriction without reversing the bradykinin-driven permeability mechanism; the paradoxical onset after 14 months of uneventful use is consistent with ACEi angioedema, which can occur at any time when bradykinin pathway sensitivity increases due to intercurrent factors; lisinopril must be permanently discontinued and never restarted or replaced with another ACEi; icatibant, a selective competitive B2 receptor antagonist (30 mg subcutaneously), directly blocks the mediator driving vascular permeability and is the targeted pharmacological intervention; fresh frozen plasma (FFP), which contains functional ACE and carboxypeptidase N capable of degrading accumulated bradykinin, is a reasonable alternative when icatibant is unavailable; airway management takes priority and the threshold for intubation or surgical airway should be low given the degree of tongue swelling.
Option A: Option A is incorrect because ACEi angioedema is bradykinin-mediated, not IgE-mediated; the absence of urticaria, the non-pruritic quality, and the failure of antihistamines and epinephrine all confirm a non-histaminergic mechanism; higher-dose epinephrine and corticosteroids will not reverse bradykinin-driven vascular permeability and delay definitive treatment.
Option B: Option B is incorrect because this is ACEi-induced angioedema from impaired bradykinin degradation, not hereditary angioedema (HAE) from C1-esterase inhibitor deficiency; while both conditions involve bradykinin accumulation and share clinical features, HAE requires inherited C1 inhibitor deficiency as the underlying etiology; this patient's presentation is most parsimoniously explained by lisinopril use without invoking an inherited complement deficiency; C1-esterase inhibitor concentrate would be appropriate for confirmed HAE.
Option D: Option D is incorrect because the angioedema is caused by bradykinin accumulation from impaired ACE-mediated degradation, not by angiotensin II accumulation; ARBs block AT1 receptors downstream of Ang II generation and do not affect bradykinin metabolism; intravenous ARB administration is not a recognized treatment for ACEi angioedema.
Option E: Option E is incorrect because lisinopril must be permanently discontinued — dose reduction does not eliminate the bradykinin accumulation mechanism and continuing any ACEi after an angioedema episode carries risk of recurrence, potentially with fatal laryngeal involvement; tranexamic acid inhibits plasminogen activation and has a role in HAE prophylaxis by reducing contact system activation, but it is not the appropriate acute intervention for established ACEi-induced oropharyngeal bradykinin-mediated angioedema.
2. A 72-year-old man with atherosclerotic vascular disease, hypertension, and known bilateral renal artery stenosis presents with acute kidney injury five days after his primary care physician started enalapril 5 mg twice daily for blood pressure control. His creatinine has risen from 1.6 to 5.1 mg/dL. He is oliguric. Imaging confirms intact bilateral renal artery stent patency. Which of the following correctly identifies the pharmacological contraindication that was violated, its mechanism, and the immediate management priority?
A) Enalapril was contraindicated because it is a prodrug that undergoes hepatic activation to enalaprilat, and patients with atherosclerotic vascular disease have reduced hepatic blood flow that impairs prodrug conversion, producing paradoxically elevated enalapril levels that are directly nephrotoxic at high concentrations
B) Enalapril was contraindicated because patients with bilateral renal artery stenosis have high circulating bradykinin levels from chronic endothelial injury, and ACEi-induced further bradykinin accumulation produces direct tubular toxicity through B2 receptor-mediated mitochondrial disruption in proximal tubular cells, causing the observed AKI
C) Enalapril was contraindicated because bilateral renal artery stenosis activates the RAAS maximally, and ACEi in this setting cause rebound angiotensin II surges from interrupted negative feedback that produce severe efferent arteriolar vasoconstriction and ischemic tubular necrosis
D) Enalapril was contraindicated because bilateral renal artery stenosis reduces the filtered sodium load to the macula densa, and ACEi suppress the compensatory tubuloglomerular feedback response that normally maintains GFR by increasing afferent arteriolar resistance; the loss of this feedback collapses GFR in bilateral RAS
E) Bilateral renal artery stenosis is an absolute contraindication to ACEi because reduced perfusion pressure distal to bilateral stenoses obligates the kidney to rely on angiotensin II-mediated efferent arteriolar constriction to maintain intraglomerular pressure and sustain GFR; enalapril suppresses angiotensin II generation, eliminating this efferent compensatory tone and causing intraglomerular pressure and GFR to collapse precipitously; enalapril must be stopped immediately, volume status assessed and optimized, and renal function monitored closely with consideration of renal replacement therapy given the degree of AKI
ANSWER: E
Rationale:
Bilateral renal artery stenosis is an absolute contraindication to ACEi therapy, and this case illustrates the mechanism directly: in bilateral RAS, reduced perfusion pressure distal to both stenoses means that the glomerular filtration rate is critically dependent on the intraglomerular hydrostatic pressure maintained by angiotensin II-mediated efferent arteriolar constriction; angiotensin II acts at AT1 receptors on efferent arteriolar smooth muscle, constricting the efferent outflow vessel and raising intraglomerular pressure against the reduced afferent inflow pressure — this is the sole adaptive mechanism sustaining GFR in this anatomical situation; enalapril inhibits ACE, reducing angiotensin II generation; without efferent arteriolar tone, intraglomerular pressure collapses, GFR falls precipitously, and AKI develops rapidly and severely — a 3-fold creatinine rise in 5 days, with oliguria, is the expected consequence; immediate management requires stopping enalapril, assessing and optimizing volume status (avoiding NSAID use and other nephrotoxins), and monitoring renal function closely with a low threshold for nephrology consultation and renal replacement therapy given the degree of AKI; recovery of renal function after ACEi discontinuation is common if the drug is stopped promptly before ischemic tubular necrosis supervenes.
Option A: Option A is incorrect because enalapril's contraindication in bilateral RAS is not related to impaired prodrug activation; hepatic esterase conversion of enalapril to enalaprilat is preserved in atherosclerotic vascular disease, and enalapril is not directly nephrotoxic through elevated parent drug concentrations — the mechanism of AKI is entirely hemodynamic.
Option B: Option B is incorrect because the mechanism of AKI in bilateral RAS from ACEi is hemodynamic collapse of intraglomerular pressure, not bradykinin-mediated tubular mitochondrial toxicity; bradykinin accumulation in bilateral RAS patients is not elevated at baseline, and B2 receptor-mediated tubular toxicity is not a recognized mechanism of ACEi nephrotoxicity.
Option C: Option C is incorrect because ACEi do not cause rebound angiotensin II surges after discontinuation of negative feedback — they reduce Ang II by blocking ACE; rebound RAAS hyperactivation after stopping ACEi does not cause the severe AKI seen here; the mechanism is loss of efferent arteriolar tone from reduced Ang II, not increased Ang II causing efferent vasoconstriction.
Option D: Option D is incorrect because ACEi do not suppress tubuloglomerular feedback to collapse GFR by increasing afferent resistance; tubuloglomerular feedback operates through the macula densa sensing sodium chloride delivery and adjusting afferent arteriolar tone via adenosine; ACEi's effect on GFR in bilateral RAS operates through efferent arteriolar dilation from Ang II reduction, not through disruption of afferent tubuloglomerular feedback.
3. A 55-year-old woman with type 1 diabetes mellitus and macroproteinuria has a creatinine clearance (CrCl) of 18 mL/min and blood pressure of 152/94 mmHg. She is currently prescribed captopril 25 mg three times daily but reports frequently missing her midday dose. Her urinary albumin-to-creatinine ratio has worsened over the past six months. Her nephrologist identifies both a pharmacokinetic problem with the current regimen and an agent-selection problem for her degree of renal impairment. Which of the following correctly identifies both issues and the optimal pharmacological change?
A) Captopril's plasma half-life of approximately 2 hours necessitates three-times-daily dosing to maintain continuous ACE inhibition, making missed midday doses a pharmacokinetically significant gap in renoprotection; additionally, captopril requires dose reduction at CrCl below 30 mL/min due to its partial renal elimination, meaning the current dose may be accumulating at a CrCl of 18 mL/min; fosinopril is the pharmacokinetically optimal alternative — its dual hepatic and biliary elimination prevents accumulation at CrCl of 18 mL/min (dose adjustment not required until CrCl below 10 mL/min), and once-daily dosing eliminates the midday adherence gap
B) Captopril's food interaction is the primary pharmacokinetic problem — if this patient takes captopril with meals, bioavailability decreases substantially; switching to enalapril once daily resolves both the food interaction and the dosing frequency problem, and enalaprilat's dual hepatic-renal elimination makes it pharmacokinetically safe at a CrCl of 18 mL/min without dose adjustment
C) The primary problem is that captopril's sulfhydryl group reduces its renal tubular reabsorption in patients with CKD (chronic kidney disease), causing it to accumulate in tubular fluid and produce direct tubular toxicity; lisinopril, which uses a carboxylate zinc ligand and is active as administered, avoids this problem and can be given once daily without dose adjustment at CrCl of 18 mL/min
D) Captopril is an appropriate agent at CrCl of 18 mL/min because its partial renal elimination is compensated by hepatic metabolism; the only problem is adherence with the TID regimen; the optimal solution is to switch to sustained-release captopril once daily, which provides the same 24-hour ACE inhibition with a single daily dose and eliminates the midday adherence gap
E) The pharmacokinetic problem is that captopril's sulfhydryl group undergoes rapid oxidation in patients with diabetic nephropathy, producing disulfide metabolites that inhibit tubular potassium secretion and cause progressive hyperkalemia; switching to ramipril eliminates the oxidation problem and provides once-daily dosing, and ramiprilat's predominantly hepatic elimination makes dose adjustment unnecessary at CrCl of 18 mL/min
ANSWER: A
Rationale:
This patient has two simultaneous pharmacological problems with her current captopril regimen: the first is a pharmacokinetic adherence issue — captopril's plasma half-life of approximately 2 hours requires three-times-daily dosing to maintain sustained ACE inhibition, and missing the midday dose creates a clinically significant gap of several hours without adequate ACE inhibition, potentially allowing intraglomerular pressure and proteinuria to increase during that interval; the second is agent-selection — captopril partially relies on renal elimination and the FDA label recommends dose reduction at CrCl below 30 mL/min to prevent accumulation; at a CrCl of 18 mL/min, captopril may accumulate to concentrations above those intended, and the current 25 mg TID dose may require adjustment; fosinopril addresses both problems simultaneously: fosinoprilat, the active metabolite, undergoes dual elimination through approximately equal hepatic/biliary and renal pathways, meaning that as renal clearance declines, biliary elimination compensates proportionally and accumulation does not occur disproportionately — dose adjustment is not required until CrCl falls below 10 mL/min, making fosinopril safe at CrCl of 18 mL/min without modification; fosinopril's once-daily dosing eliminates the missed midday dose adherence gap; the class-effect renoprotection established by the Lewis trial (efferent arteriolar dilation reducing intraglomerular pressure) applies equally to fosinopril.
Option B: Option B is incorrect because enalaprilat is not eliminated by dual hepatic-renal pathways — it is predominantly renally eliminated and accumulates in CKD, requiring dose reduction at CrCl below 30 mL/min; enalapril at CrCl of 18 mL/min requires dose reduction, not standard dosing without adjustment; additionally, while enalapril can be dosed once daily, the claim of dual elimination for enalaprilat is pharmacokinetically incorrect.
Option C: Option C is incorrect because captopril's sulfhydryl group does not reduce renal tubular reabsorption or produce tubular toxicity; the SH-related adverse effects of captopril are rash and dysgeusia, not renal tubular accumulation injury; lisinopril is exclusively renally eliminated and accumulates significantly at CrCl of 18 mL/min, requiring dose reduction — it is not appropriate to use lisinopril without dose adjustment at this degree of renal impairment.
Option D: Option D is incorrect because sustained-release captopril is not a clinically available formulation; captopril is only available in immediate-release form; there is no sustained-release captopril preparation that would provide once-daily dosing.
Option E: Option E is incorrect because captopril's sulfhydryl group does not undergo clinically significant oxidation to hyperkalemia-inducing disulfide metabolites in diabetic nephropathy; this proposed mechanism is not an established adverse effect of captopril; and ramiprilat is predominantly renally eliminated and requires dose adjustment in significant renal impairment — it does not have predominantly hepatic elimination that would make it safe without adjustment at CrCl of 18 mL/min.
4. A 48-year-old man with bipolar I disorder maintained on lithium carbonate 900 mg twice daily presents with a three-day history of coarse tremor, confusion, slurred speech, and polyuria. His medications were changed six weeks ago when ramipril was added for newly diagnosed hypertension and hydrochlorothiazide (HCTZ) 25 mg daily was added for edema. His serum lithium level is 2.6 mEq/L (therapeutic range 0.6–1.2 mEq/L). Serum creatinine is mildly elevated at 1.4 mg/dL. Which of the following correctly identifies the pharmacological mechanism of lithium toxicity in this patient?
A) Ramipril inhibits CYP3A4-mediated oxidative metabolism of lithium in the kidney, reducing renal lithium clearance; HCTZ independently inhibits the same CYP3A4 pathway in renal tubular cells, producing additive impairment of lithium oxidation and doubling the accumulation rate compared to either drug alone
B) Ramipril's bradykinin accumulation activates B2 receptors on proximal tubular cells, upregulating the luminal sodium-hydrogen exchanger to a degree that non-selectively increases reabsorption of all cations including lithium; HCTZ amplifies this by directly stimulating the same exchanger through a thiazide-specific tubular receptor
C) HCTZ causes direct sodium depletion in the loop of Henle through NKCC2 (Na-K-2Cl cotransporter) inhibition, creating a volume-depleted state in which the kidney maximally reabsorbs sodium and lithium in the collecting duct via aldosterone-stimulated ENaC (epithelial sodium channel); ramipril compounds this by simultaneously blocking aldosterone secretion, paradoxically increasing collecting duct sodium and lithium reabsorption through an unknown non-aldosterone mechanism
D) Ramipril suppresses aldosterone, reducing distal sodium reabsorption and triggering compensatory upregulation of proximal tubular sodium reabsorption via the sodium-hydrogen exchanger; lithium, handled similarly to sodium in the proximal tubule, is reabsorbed in parallel, reducing urinary lithium excretion; HCTZ independently causes natriuresis and volume depletion through inhibition of the thiazide-sensitive sodium-chloride cotransporter in the distal convoluted tubule, which triggers a compensatory increase in proximal tubular sodium reabsorption as the kidney attempts to restore effective arterial volume; this second compensatory mechanism further increases proximal lithium reabsorption, producing additive lithium retention from two converging pathways acting through the same proximal tubular reabsorptive mechanism
E) Both ramipril and HCTZ reduce GFR (glomerular filtration rate) by decreasing systemic blood pressure, reducing the filtered lithium load below the kidney's capacity to maintain adequate urinary excretion; the lithium toxicity is explained entirely by reduced filtration rather than increased tubular reabsorption, and would occur equally with any two antihypertensive agents that lower blood pressure by a similar degree
ANSWER: D
Rationale:
This case demonstrates convergent proximal tubular lithium retention from two pharmacologically distinct but mechanistically additive pathways: ramipril, an ACEi, suppresses angiotensin II generation and thereby reduces aldosterone secretion from the adrenal zona glomerulosa; without aldosterone, ENaC-mediated distal collecting duct sodium reabsorption is reduced; the kidney compensates by upregulating proximal tubular sodium reabsorption through the sodium-hydrogen exchanger (NHE3) to maintain sodium homeostasis; because lithium enters proximal tubular cells through sodium-coupled transport mechanisms and is handled similarly to sodium in the proximal nephron, the compensatory increase in proximal sodium reabsorption carries lithium with it, reducing urinary lithium excretion and raising serum lithium; hydrochlorothiazide (HCTZ) adds a second independent mechanism: by inhibiting the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, HCTZ produces natriuresis and volume contraction; volume contraction activates baroreceptors, the sympathetic nervous system, and the RAAS (though this latter pathway is partially blunted by ramipril), all of which signal the proximal tubule to increase sodium reabsorption as a compensatory response to restore effective arterial volume; this volume-depletion-driven proximal sodium reabsorption again carries lithium in parallel, further reducing urinary lithium clearance; the two drugs produce additive lithium retention through converging effects on the same proximal tubular reabsorptive pathway, explaining why the combination produces more severe toxicity than either drug alone; serum lithium monitoring within 1–2 weeks of initiating or changing either drug is mandatory in lithium-maintained patients.
Option A: Option A is incorrect because lithium is an elemental ion that is not metabolized by CYP3A4 or any cytochrome P450 enzyme; lithium is excreted entirely as the lithium ion without biotransformation; neither ramipril nor HCTZ inhibits CYP3A4-mediated lithium metabolism because no such pathway exists.
Option B: Option B is incorrect because bradykinin accumulation from ACEi does not upregulate proximal tubular NHE3 through B2 receptor activation as a recognized pharmacological mechanism; the ACEi-lithium interaction operates through aldosterone suppression driving compensatory proximal sodium reabsorption, not through bradykinin-mediated transporter upregulation.
Option C: Option C is incorrect because HCTZ inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, not NKCC2 in the loop of Henle — NKCC2 inhibition is the mechanism of loop diuretics (furosemide, bumetanide); and the proposed mechanism of ramipril paradoxically increasing collecting duct reabsorption through a non-aldosterone mechanism is not established pharmacology.
Option E: Option E is incorrect because the lithium toxicity is not explained primarily by reduced filtered load from lower blood pressure; the dominant mechanism is increased proximal tubular reabsorption from the two converging pathways described; other antihypertensive agents that lower blood pressure through mechanisms not involving RAAS suppression or volume depletion (such as amlodipine) do not produce equivalent lithium toxicity, confirming that the mechanism is tubular reabsorption-specific rather than a generic GFR-reduction effect.
5. A 31-year-old woman with chronic hypertension presents for her first prenatal visit at 10 weeks gestation. She has been taking enalapril 10 mg daily for three years and was not aware she was pregnant. Her blood pressure today is 138/88 mmHg. She asks what specific risks the enalapril has posed to the fetus during the first trimester and whether it is safe to continue during the rest of the pregnancy. Which of the following correctly counsels her on trimester-specific fetal risk and the required management change?
A) Enalapril is safe throughout the first trimester because fetal renal development and RAAS activity do not begin until approximately 14 weeks gestation; the risk of fetal renal tubular dysgenesis applies only to second and third trimester exposure; she should continue enalapril until 14 weeks and then switch to methyldopa or nifedipine, which are established safe antihypertensives in pregnancy
B) First-trimester enalapril exposure is associated with increased risk of cardiovascular and CNS (central nervous system) structural malformations in the fetus during organogenesis; second and third trimester exposure causes fetal renal tubular dysgenesis through suppression of fetal RAAS-dependent renal development, leading to oligohydramnios, fetal anuria, pulmonary hypoplasia, and potentially fatal neonatal renal failure; enalapril must be discontinued immediately regardless of gestational age, a detailed fetal anatomic ultrasound should be arranged to assess for structural malformations from the first-trimester exposure, and safe antihypertensive alternatives such as labetalol, methyldopa, or nifedipine should be initiated
C) Enalapril exposure during the first trimester is associated with oligohydramnios and fetal anuria from suppression of fetal RAAS-dependent renal tubular development; she should discontinue enalapril immediately and arrange urgent amniocentesis to assess amniotic fluid alpha-fetoprotein levels for evidence of renal tubular injury, and switch to an ARB (angiotensin receptor blocker) which does not suppress the fetal RAAS because it acts downstream of angiotensin II generation
D) Enalapril carries fetal risk only at doses exceeding 20 mg daily in the first trimester; her dose of 10 mg daily is below the threshold for fetal organogenesis toxicity, and she may continue enalapril through the first trimester; she should switch to an ARB in the second trimester, as ARBs do not produce bradykinin accumulation and are therefore safe in pregnancy beyond 12 weeks gestation
E) Enalapril is a Class B medication in pregnancy with no established fetal risk in controlled human studies; the theoretical risk of fetal RAAS suppression has not been confirmed in prospective randomized trials; she may continue enalapril throughout pregnancy with monthly fetal ultrasound monitoring for oligohydramnios as an adequate safety measure
ANSWER: B
Rationale:
ACEi are absolutely contraindicated throughout all three trimesters of pregnancy, and this counseling must be unambiguous: first-trimester exposure during the critical window of organogenesis (weeks 3–8 in particular) has been associated in pharmacoepidemiological cohort studies with increased incidence of cardiovascular malformations (ventricular septal defects, patent ductus arteriosus) and CNS malformations in infants, likely reflecting a developmental role of angiotensin II signaling in normal cardiovascular and neural tube morphogenesis; this patient has had 10 weeks of enalapril exposure, covering the full organogenesis window; second and third trimester exposure causes fetal renal tubular dysgenesis through suppression of fetal RAAS-dependent renal development — the developing fetal kidney requires angiotensin II signaling at AT1 receptors for normal tubular morphogenesis, and ACEi-mediated fetal RAAS suppression impairs this, resulting in oligohydramnios (from fetal anuria as the kidneys fail to produce urine), limb contractures, pulmonary hypoplasia (from reduced amniotic fluid available for fetal lung development), and potentially fatal neonatal anuria and hypotension; enalapril must be discontinued immediately; a detailed anatomic fetal ultrasound should be arranged to assess for cardiac and CNS structural abnormalities resulting from the first-trimester exposure; safe antihypertensive alternatives in pregnancy include labetalol, methyldopa, and nifedipine.
Option A: Option A is incorrect because the first-trimester risk of ACEi is structural malformations during organogenesis, not renal tubular dysgenesis — the malformations described (cardiac, CNS) occur during the first trimester, not after 14 weeks; continuing enalapril until 14 weeks would extend the organogenesis exposure and begin the period of fetal renal risk; there is no safe window for continued ACEi use in pregnancy.
Option C: Option C is incorrect on two counts: the first-trimester risk is cardiac and CNS malformations during organogenesis, not oligohydramnios and fetal anuria (those are second/third trimester risks from renal RAAS suppression); and ARBs are equally contraindicated in pregnancy — they also suppress fetal RAAS-dependent renal development through AT1 receptor blockade and produce the same fetal renal toxic effects as ACEi; ARBs are not safe alternatives in pregnancy.
Option D: Option D is incorrect because enalapril's fetal toxicity is not dose-dependent above a threshold at 20 mg/day — all doses of ACEi are contraindicated throughout pregnancy regardless of dose; there is no established safe dose for ACEi in pregnancy, and dose reduction does not mitigate the organogenesis risk.
Option E: Option E is incorrect because ACEi are not Class B medications — they are formally contraindicated in pregnancy (the FDA updated pregnancy labeling for ACEi to reflect this, and current prescribing information carries a black box warning against use in pregnancy); the characterization of theoretical risk not confirmed in prospective randomized trials misrepresents the regulatory status; monthly ultrasound monitoring does not make continuation safe.
6. A 58-year-old man with HFrEF (heart failure with reduced ejection fraction, ejection fraction 28%) is on enalapril 10 mg twice daily and spironolactone 25 mg daily. At his four-week follow-up his serum potassium is 5.7 mEq/L (up from 4.6 mEq/L at baseline) and his creatinine has risen from 1.3 to 1.6 mg/dL (a 23% increase). He is hemodynamically stable, euvolemic on examination, and asymptomatic. Which of the following correctly interprets both laboratory changes and identifies the appropriate management response?
A) Both findings indicate that the enalapril dose is too high: the 23% creatinine rise confirms excessive efferent arteriolar dilation reducing GFR (glomerular filtration rate) beyond the acceptable threshold, and the potassium of 5.7 mEq/L confirms excessive aldosterone suppression; both drugs should be discontinued immediately and the patient referred to nephrology before restarting any RAAS therapy
B) The potassium of 5.7 mEq/L is the only finding requiring action; the 23% creatinine rise is within the acceptable range and should be ignored; spironolactone should be discontinued immediately because it is not indicated in HFrEF without documented aldosterone excess, and its removal will resolve the hyperkalemia without affecting the creatinine
C) The creatinine rise of 23% is within the acceptable range (below the approximately 30% threshold) and reflects expected efferent arteriolar dilation reducing glomerular hyperfiltration rather than nephrotoxic injury; however, the potassium of 5.7 mEq/L crosses the 5.5 mEq/L hold threshold for ACEi therapy; enalapril should be held, spironolactone dose reviewed and reduced or held, dietary potassium restriction reinforced, potassium-containing salt substitutes avoided, and electrolytes rechecked before restarting enalapril at a lower dose
D) Both findings are within acceptable pharmacodynamic parameters for a patient on dual neurohormonal blockade with HFrEF: a creatinine rise of up to 30% and a potassium of up to 6.0 mEq/L are acceptable in HFrEF patients on ACEi plus spironolactone because the mortality benefit of neurohormonal blockade outweighs the risk at these levels; no medication changes are required and repeat labs should be obtained at 12 weeks
E) Both findings indicate that spironolactone is the sole cause of the laboratory changes: spironolactone's mineralocorticoid receptor blockade directly impairs proximal tubular sodium-potassium exchange, simultaneously reducing GFR and potassium excretion; enalapril is not contributing to either finding because ACEi do not affect renal tubular potassium handling when used without concurrent diuretics
ANSWER: C
Rationale:
This case requires applying two independent monitoring thresholds simultaneously and correctly identifying which requires action and which does not: the creatinine rise of 23% falls below the approximately 30% threshold that distinguishes acceptable efferent arteriolar dilation-related GFR reduction from pathological hemodynamic AKI (acute kidney injury) — a 23% rise in a patient with HFrEF on enalapril is within the expected pharmacodynamic range reflecting reduced glomerular hyperfiltration, not nephrotoxic injury; it does not by itself require enalapril discontinuation; however, the potassium of 5.7 mEq/L has crossed the 5.5 mEq/L hold threshold for ACEi therapy — this threshold exists because potassium above this level requires action before rising further toward the arrhythmia risk range above 6.0 mEq/L; the hyperkalemia reflects additive aldosterone suppression from enalapril (which reduces angiotensin II-driven aldosterone secretion) and spironolactone (which blocks the mineralocorticoid receptor in collecting duct principal cells), compounded by the patient's reduced nephron mass from CKD; enalapril should be held, spironolactone dose evaluated (dose reduction from 25 to 12.5 mg or temporary hold), dietary potassium restriction reinforced with particular attention to potassium-containing salt substitutes, and electrolytes rechecked before restarting enalapril at a lower dose; both drugs should ultimately be restarted given the mortality benefit of ACEi plus MRA (mineralocorticoid receptor antagonist) in HFrEF.
Option A: Option A is incorrect because the 23% creatinine rise does not cross the approximately 30% threshold requiring discontinuation; it is within the acceptable range; discontinuing both drugs based on a creatinine rise below the threshold would inappropriately deprive this patient of the substantial mortality benefit of neurohormonal blockade in HFrEF.
Option B: Option B is incorrect because spironolactone is indicated in HFrEF at ejection fraction below 35% with NYHA class II-IV symptoms, as established by the RALES trial — it should not be discontinued on the basis of a single potassium elevation that can be managed; furthermore, enalapril, not only spironolactone, contributes to the hyperkalemia through aldosterone suppression; discontinuing spironolactone alone addresses only part of the potassium problem.
Option D: Option D is incorrect because the potassium hold threshold of 5.5 mEq/L applies to HFrEF patients on neurohormonal blockade as much as to other patients; while the mortality benefit of dual neurohormonal blockade is substantial, it does not justify accepting potassium of 5.7 mEq/L without action; 6.0 mEq/L is the discontinuation threshold, not an acceptable steady-state level in the context of rising potassium trend.
Option E: Option E is incorrect because enalapril does contribute to hyperkalemia through aldosterone suppression — ACEi reduce angiotensin II, which is the primary stimulus for aldosterone secretion, and reduced aldosterone in collecting duct principal cells impairs potassium secretion; this mechanism is independent of diuretic use; spironolactone alone does not impair proximal tubular GFR.
7. A 44-year-old Japanese woman with hypertension has been on ramipril 5 mg daily for eight weeks and develops a persistent dry, tickling cough. Her primary care physician, uncertain of the cause, prescribes codeine 30 mg every six hours as a cough suppressant. Four weeks later the cough is unchanged and she returns. Which of the following correctly explains why codeine was ineffective for this cough and identifies the correct management?
A) The cough is caused by bradykinin accumulation from ACE inhibition activating B2 receptors on airway sensory C-fibers and increasing prostaglandin E2 and thromboxane A2, which sensitize the cough reflex arc below the level at which opioid receptor agonism at mu-receptors in the brainstem cough center can suppress it; codeine's antitussive effect operates through central mu-receptor activation to raise the cough threshold, but the peripheral afferent sensitization from bradykinin-driven eicosanoid generation at C-fiber terminals creates a cough stimulus that is disproportionately strong relative to what central opioid suppression can overcome; the correct management is to discontinue ramipril and switch to an ARB (angiotensin receptor blocker), which resolves the cough by restoring normal ACE-mediated bradykinin degradation
B) Codeine was ineffective because this patient is a CYP2D6 ultrarapid metabolizer, a genotype more common in Japanese populations, causing codeine to be converted so rapidly to morphine that morphine glucuronidation cannot keep pace and morphine accumulates to sedating levels before achieving cough suppression; the correct management is to switch to dextromethorphan, which does not require CYP2D6 activation, and continue ramipril at a reduced dose
C) The cough is caused by bradykinin-mediated histamine release from airway mast cells; codeine, which has mild antihistamine properties at high doses, was underdosed at 30 mg every six hours; increasing codeine to 60 mg every four hours would achieve sufficient H1 receptor blockade to suppress the mast cell-driven cough; if codeine is ineffective at higher doses, switching to a non-sedating antihistamine such as cetirizine is the preferred next step
D) The cough is caused by ACEi-induced angiotensin I accumulation proximal to the ACE block that directly activates AT1 receptors on bronchial afferent neurons; codeine cannot suppress this cough because opioid receptors are not expressed on bronchial AT1 receptor-bearing neurons; the correct management is to add an ARB to the current ramipril regimen, which will block accumulated angiotensin I at the bronchial AT1 receptor while maintaining systemic RAAS blockade
E) Codeine was ineffective because ACEi-induced cough in Japanese patients is mediated by a prostaglandin-independent pathway involving direct C-fiber activation by angiotensin II fragments generated proximal to the ACE block; this population-specific pathway does not respond to any antitussive and requires discontinuation of ramipril without substitution, as ARBs also produce this cough in East Asian patients through the same non-bradykinin mechanism
ANSWER: A
Rationale:
ACEi-induced cough is caused by bradykinin accumulation in pulmonary tissues resulting from ACE (kininase II) inhibition by ramipril; accumulated bradykinin activates B2 receptors on airway sensory C-fiber nerve terminals, triggering arachidonic acid release via phospholipase A2 and generating prostaglandin E2 (PGE2) and thromboxane A2 (TXA2) locally; these eicosanoids sensitize the bronchial afferent cough reflex arc by lowering the activation threshold of C-fiber mechanoreceptors and chemoreceptors; codeine exerts its antitussive effect primarily through mu-opioid receptor agonism in the brainstem cough center (nucleus tractus solitarius and related areas), raising the central threshold for cough reflex activation; however, the peripheral sensitization of airway C-fibers by bradykinin-driven prostaglandin generation creates an afferent cough stimulus of sufficient intensity that central mu-receptor-mediated threshold elevation is overwhelmed — the peripheral drive exceeds what codeine's central suppression can overcome; this is why antitussives including codeine, dextromethorphan, and benzonatate are clinically ineffective for ACEi cough; this patient's East Asian (Japanese) ancestry is relevant: ACEi cough occurs in approximately 30–40% of East Asian patients compared to 5–10% of European patients, reflecting pharmacogenomic differences in bradykinin pathway sensitivity; the only effective management is to discontinue ramipril and switch to an ARB, which does not inhibit ACE and allows normal ACE-mediated bradykinin degradation to resume, resolving the cough in virtually all patients within days to weeks.
Option B: Option B is incorrect because Japanese patients are not characterized by a high prevalence of CYP2D6 ultrarapid metabolizer status — in fact, Japanese populations have a relatively low prevalence of CYP2D6 ultrarapid metabolism compared to some other populations; and the failure of codeine for ACEi cough is not pharmacokinetic but mechanistic — the cough stimulus is peripheral and prostaglandin-driven, beyond the reach of central opioid suppression regardless of codeine metabolism rate.
Option C: Option C is incorrect because ACEi cough is not mediated by bradykinin-induced histamine release from airway mast cells; the mechanism is direct B2 receptor activation on C-fibers driving prostaglandin synthesis, not histaminergic mast cell degranulation; antihistamines are clinically ineffective for ACEi cough, and increasing codeine dose or adding cetirizine will not address the underlying peripheral prostaglandin-driven C-fiber sensitization.
Option D: Option D is incorrect because angiotensin I does not directly activate AT1 receptors on bronchial afferent neurons — AT1 receptors bind angiotensin II, not angiotensin I; and adding an ARB to ramipril constitutes dual RAAS blockade, which is not recommended given the ONTARGET-demonstrated increased risks of AKI, hyperkalemia, and hypotension without cardiovascular benefit from this combination.
Option E: Option E is incorrect because ACEi cough in Japanese and other East Asian patients is bradykinin-mediated and prostaglandin-dependent, not caused by a distinct angiotensin II fragment pathway; ARBs reliably resolve ACEi cough in East Asian patients — this is clinically well established — because ARBs restore normal ACE-mediated bradykinin degradation by not inhibiting ACE; the claim that ARBs produce the same cough in East Asian patients is factually incorrect.
8. A 70-year-old man with type 2 diabetes mellitus, hypertension, and CKD (chronic kidney disease) stage 3a is seen by a new internist who adds aliskiren 150 mg daily to his existing regimen of lisinopril 20 mg daily, aiming to achieve more complete RAAS suppression and further reduce his urinary albumin-to-creatinine ratio. Three weeks later the patient presents to the emergency department with nausea, dizziness, and weakness. His serum potassium is 6.1 mEq/L, creatinine has risen from 1.5 to 2.8 mg/dL, and blood pressure is 88/54 mmHg. Which of the following correctly identifies the prescribing error, its regulatory basis, and the mechanism of each laboratory finding?
A) The prescribing error was adding aliskiren to lisinopril in a patient with CKD stage 3a; aliskiren is specifically contraindicated in patients with CrCl below 60 mL/min because it accumulates in renal impairment due to its partial renal elimination, reaching concentrations that cause direct tubular toxicity; the AKI, hyperkalemia, and hypotension all result from aliskiren accumulation rather than from pharmacodynamic RAAS over-suppression
B) The prescribing error was adding aliskiren to lisinopril without first discontinuing amlodipine; aliskiren is contraindicated when combined with calcium channel blockers in patients with type 2 diabetes because amlodipine inhibits P-gp-mediated aliskiren efflux, increasing aliskiren concentrations to toxic levels; the laboratory findings reflect aliskiren accumulation from this P-gp interaction
C) The prescribing error was starting aliskiren at 150 mg rather than the mandatory 75 mg starting dose in patients with type 2 diabetes and CKD; at 150 mg the RAAS suppression exceeds a safety threshold, causing dose-dependent AKI, hyperkalemia, and hypotension; at the approved starting dose of 75 mg, aliskiren can be safely combined with ACEi in patients with type 2 diabetes
D) The prescribing error was combining aliskiren with lisinopril in a patient without prior documentation of inadequate blood pressure control on lisinopril monotherapy; the FDA requires documented monotherapy failure before dual RAAS blockade can be initiated; the mechanism of the laboratory findings is reflex sympathetic withdrawal from excessive blood pressure lowering rather than pharmacodynamic RAAS over-suppression
E) The prescribing error was combining aliskiren with lisinopril in a patient with type 2 diabetes, which is explicitly contraindicated based on the ALTITUDE trial demonstrating that this combination increased rates of AKI, hyperkalemia, and hypotension without reducing cardiovascular or renal endpoints compared to ACEi monotherapy; the potassium of 6.1 mEq/L reflects additive aldosterone suppression from dual RAAS blockade reducing collecting duct potassium secretion, the creatinine rise reflects combined hemodynamic reduction in intraglomerular pressure from dual RAAS suppression in the setting of CKD, and the hypotension reflects excessive systemic vasodilatation from combined angiotensin II suppression; aliskiren must be discontinued immediately
ANSWER: E
Rationale:
The ALTITUDE trial (Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints) established the clinical and regulatory basis for the contraindication against combining aliskiren with ACEi or ARBs in patients with type 2 diabetes: the trial enrolled patients with type 2 diabetes and CKD or cardiovascular disease who were already on ACEi or ARB therapy, and randomized them to add aliskiren or placebo; the aliskiren combination arm showed significantly increased rates of AKI (acute kidney injury), hyperkalemia, and hypotension without any reduction in the primary cardiovascular or renal composite endpoints; regulatory agencies issued a formal contraindication against this combination in patients with diabetes; this patient's presentation exemplifies exactly the harm profile identified in ALTITUDE: the potassium of 6.1 mEq/L results from additive suppression of aldosterone by both lisinopril (reducing angiotensin II-driven aldosterone secretion) and aliskiren (reducing all downstream RAAS components including aldosterone), producing additive impairment of collecting duct principal cell potassium secretion through reduced ENaC expression and sodium-potassium ATPase activity; the creatinine rise reflects combined efferent arteriolar dilation from dual Ang II suppression reducing intraglomerular pressure, superimposed on pre-existing CKD; the hypotension reflects excessive systemic vasodilatation from combined angiotensin II suppression at the vascular AT1 receptor; aliskiren must be discontinued immediately and the patient managed supportively for hyperkalemia, AKI, and hypotension.
Option A: Option A is incorrect because aliskiren does not cause AKI through direct tubular toxicity from accumulation; aliskiren is predominantly eliminated via the hepatobiliary route with minimal renal excretion, so it does not accumulate in renal impairment in a way that produces tubular toxicity; the mechanism of harm from the combination is pharmacodynamic over-suppression of the RAAS, not drug accumulation-mediated nephrotoxicity.
Option B: Option B is incorrect because the prescribing error was the ACEi-aliskiren combination in a diabetic patient, not a non-existent interaction with amlodipine; while aliskiren is a P-gp substrate and P-gp inhibitors such as verapamil and ketoconazole can increase aliskiren concentrations, amlodipine is not a recognized clinically significant P-gp inhibitor, and the patient's presentation reflects ALTITUDE-established dual RAAS blockade harm, not a P-gp interaction.
Option C: Option C is incorrect because there is no approved 75 mg starting dose of aliskiren specifically for type 2 diabetes with CKD, and the contraindication against combining aliskiren with ACEi in diabetic patients applies regardless of dose; there is no dose of aliskiren that is safe to combine with ACEi in patients with type 2 diabetes based on the ALTITUDE data.
Option D: Option D is incorrect because the contraindication against aliskiren-ACEi combination in diabetes is not based on a prior monotherapy failure documentation requirement but on the ALTITUDE trial safety data; the mechanism of harm is pharmacodynamic RAAS over-suppression producing AKI, hyperkalemia, and hypotension, not reflex sympathetic withdrawal.
9. A 63-year-old man with a recent anterior myocardial infarction and an ejection fraction of 25% is started on captopril 25 mg three times daily for post-MI HFrEF (heart failure with reduced ejection fraction). To minimize gastric discomfort he takes all three doses immediately after meals. At six weeks his blood pressure averages 148/92 mmHg and his symptoms of dyspnea on exertion are unchanged. His cardiologist is puzzled by the inadequate response since captopril is being taken as prescribed. Which of the following correctly identifies the pharmacokinetic error and its clinical consequence?
A) Captopril's three-times-daily dosing schedule spaces doses too close together when taken after meals; the post-meal gastric acid environment reduces captopril's sulfhydryl group to a disulfide form that is pharmacologically inactive, accumulating in plasma and producing a competitive antagonist effect at the ACE active site that partially overcomes the effect of active captopril
B) Captopril undergoes extensive hepatic first-pass metabolism when taken with high-fat meals because dietary fat stimulates bile acid secretion that induces CYP3A4, the enzyme responsible for captopril's hepatic inactivation; food-induced CYP3A4 induction reduces captopril bioavailability to near zero in the postprandial state
C) Captopril is a prodrug that requires activation by intestinal mucosal esterases; high-fat meals reduce intestinal esterase activity by saturating the enzyme with dietary triglycerides, impairing captopril-to-captoprilat conversion and reducing the plasma concentration of the pharmacologically active metabolite
D) Captopril's oral bioavailability decreases significantly when taken with food — from approximately 65–75% in the fasted state to substantially lower values in the fed state — because food delays gastric emptying, dilutes captopril in gastric contents, and may impair intestinal uptake; consistently taking captopril with meals reduces peak plasma concentrations and the degree of ACE inhibition achieved, explaining the inadequate antihypertensive and heart failure response; captopril should be taken at least one hour before or two hours after meals for reliable absorption
E) Captopril is being taken correctly and the pharmacokinetics are not responsible for the inadequate response; the problem is that captopril 25 mg three times daily is below the therapeutic dose range for post-MI HFrEF, which requires doses of at least 50 mg four times daily to achieve the target ACE inhibition demonstrated in the SAVE trial; the dose should be increased before any consideration of administration timing changes
ANSWER: D
Rationale:
Captopril's oral bioavailability in the fasted state is approximately 65–75%, but when taken with food this bioavailability decreases substantially — studies demonstrate reductions of approximately 25–35% in peak plasma concentration and area under the curve when captopril is administered with food compared to fasted administration; the mechanism reflects delayed gastric emptying in the fed state, dilution of captopril in gastric contents, and possible competition from food-derived amino acids and peptides for intestinal uptake mechanisms; because captopril has a short half-life of approximately 2 hours and requires three-times-daily dosing to maintain continuous ACE inhibition, consistent administration at adequate plasma concentrations is critical — food-induced reductions in bioavailability translate directly to reduced ACE inhibition at each dosing interval and subtherapeutic antihypertensive and hemodynamic benefit; the patient's inadequate blood pressure control and persistent dyspnea despite adherence to the prescribed schedule are consistent with pharmacokinetically reduced captopril exposure from consistently post-meal administration; the corrective action is to administer captopril at least one hour before or two hours after meals for all three daily doses; this food interaction is unique to captopril within the ACEi class — enalapril and lisinopril have minimal food interactions and can be taken without regard to meals.
Option A: Option A is incorrect because captopril's sulfhydryl group does not react with gastric acid to form a pharmacologically inactive disulfide competitive antagonist; while sulfhydryl groups can undergo oxidation to disulfides in certain chemical environments, this is not the established mechanism of captopril's food interaction, which is pharmacokinetic (reduced bioavailability) rather than pharmacodynamic (formation of an antagonist).
Option B: Option B is incorrect because captopril is not metabolized by CYP3A4 and dietary fat does not induce CYP3A4 through bile acid secretion in a clinically meaningful way; captopril's food interaction is an absorption phenomenon, not a hepatic first-pass metabolism induction mechanism.
Option C: Option C is incorrect because captopril is not a prodrug — it is the only ACEi that is pharmacologically active as administered without requiring biotransformation; there is no captoprilat metabolite, and intestinal esterase activity is not involved in captopril's pharmacological activation.
Option E: Option E is incorrect because the food interaction is a real and clinically significant pharmacokinetic factor in captopril's inadequate response in this patient; captopril 25 mg three times daily is within the range used in the SAVE trial (target 50 mg three times daily, but initiated at lower doses), and the appropriate first step is to correct the food-interaction administration error before dose escalation.
10. A 57-year-old woman with hypertension and CKD (chronic kidney disease) stage 3b from hypertensive nephrosclerosis is started on ramipril 5 mg daily. At two-week follow-up her creatinine has risen from 1.8 to 2.3 mg/dL (a 28% increase) and her serum potassium is 4.9 mEq/L. She is asymptomatic and her blood pressure is 132/78 mmHg. The covering physician, unfamiliar with ACEi pharmacology, considers stopping ramipril. Which of the following correctly interprets these findings and provides the appropriate management guidance?
A) The 28% creatinine rise confirms bilateral renal artery stenosis unmasked by ACEi initiation; ramipril must be stopped immediately and urgent renal artery duplex ultrasonography obtained; no ACEi or ARB should be restarted until stenosis is excluded by imaging
B) The 28% creatinine rise falls within the acceptable range (below approximately 30%) and reflects expected efferent arteriolar dilation-related reduction in glomerular hyperfiltration rather than nephrotoxic injury; the potassium of 4.9 mEq/L is below the 5.5 mEq/L hold threshold and does not require action; ramipril should be continued with repeat creatinine and potassium in four weeks, understanding that ACEi renoprotection in hypertensive CKD is most valuable in the same population where this creatinine rise is expected
C) The 28% creatinine rise and the potassium of 4.9 mEq/L together represent a combined nephrotoxic and hyperkalemic signal that, in concert, crosses the threshold for ACEi discontinuation even though each finding individually is below its own threshold; ramipril should be held and the combination should not be restarted
D) The creatinine rise indicates ACEi-induced hemodynamic AKI (acute kidney injury) in a patient with stage 3b CKD who lacks the renal reserve to tolerate efferent arteriolar dilation; ACEi are relatively contraindicated in patients with CrCl below 45 mL/min, and ramipril should be discontinued and replaced with amlodipine for blood pressure control
E) Both findings require immediate action: the creatinine rise indicates severe ACEi nephrotoxicity requiring ramipril discontinuation, and the potassium of 4.9 mEq/L is above the normal range and requires urgent management with sodium polystyrene sulfonate before any ACEi can be restarted in the future
ANSWER: B
Rationale:
This clinical vignette tests the ability to correctly apply both the creatinine threshold and the potassium threshold simultaneously and resist the impulse to stop a beneficial drug inappropriately: the creatinine rise of 28% falls below the approximately 30% threshold that distinguishes acceptable efferent arteriolar dilation-related GFR (glomerular filtration rate) reduction from pathological hemodynamic AKI; the mechanism is pharmacologically expected — ACEi reduce angiotensin II-mediated efferent arteriolar constriction, lowering intraglomerular pressure and reducing the compensatory hyperfiltration that was sustaining an artificially elevated GFR in the setting of hypertensive nephrosclerosis; a creatinine rise of up to 30% in this context reflects the kidney's true underlying GFR after removal of hyperfiltration and is not nephrotoxic injury; the serum potassium of 4.9 mEq/L is above the upper end of the normal reference range but below the 5.5 mEq/L threshold for ACEi dose modification or discontinuation; it does not require urgent potassium-lowering therapy or drug discontinuation; it does warrant monitoring and dietary potassium counseling; the correct management is to continue ramipril with repeat creatinine and potassium measurement at four weeks, recognizing that the very population in whom these laboratory changes are expected — CKD patients with hypertensive nephrosclerosis — is also the population in whom ACEi renoprotection is most relevant; stopping ramipril at this point would deprive the patient of long-term renoprotective benefit based on a pharmacodynamically expected and acceptable creatinine change.
Option A: Option A is incorrect because a 28% creatinine rise in a patient newly started on ACEi is not diagnostic of bilateral renal artery stenosis; it is the expected hemodynamic response to efferent arteriolar dilation reducing glomerular hyperfiltration; bilateral RAS would typically be suspected with a more severe or rapid creatinine rise (above 30% or occurring within days) or in a patient with clinical features suggesting renovascular disease; urgent vascular imaging is not warranted for a 28% creatinine rise in an otherwise stable patient.
Option C: Option C is incorrect because there is no established combined threshold that adds subthreshold creatinine and potassium findings together to trigger discontinuation; clinical guidelines apply each threshold independently; a creatinine rise below 30% and a potassium below 5.5 mEq/L do not collectively require ACEi discontinuation when each is below its own individual threshold.
Option D: Option D is incorrect because CKD stage 3b and CrCl below 45 mL/min are not relative contraindications to ACEi — in fact, ACEi are specifically recommended for renoprotection in CKD with proteinuria regardless of the stage of renal impairment (with dose adjustment as needed); the expected creatinine rise after ACEi initiation is not a sign of inadequate renal reserve.
Option E: Option E is incorrect because neither finding individually or together warrants the emergency response described; a potassium of 4.9 mEq/L is mildly elevated above normal but does not require urgent sodium polystyrene sulfonate treatment; the creatinine rise is below the discontinuation threshold and does not represent severe nephrotoxicity.
11. A 69-year-old man with hypertension controlled on aliskiren 300 mg daily is started on verapamil 240 mg daily for rate control of newly diagnosed atrial fibrillation. Verapamil is a known inhibitor of P-glycoprotein (P-gp). Three days after starting verapamil he develops symptomatic hypotension with a blood pressure of 82/50 mmHg and lightheadedness. His aliskiren dose has not been changed. Which of the following correctly identifies the mechanism of the drug interaction, explains why the hypotension occurred three days after initiation rather than immediately, and identifies the appropriate management?
A) Verapamil inhibits CYP3A4-mediated first-pass hepatic metabolism of aliskiren, the primary route of aliskiren elimination; as aliskiren accumulates over three days of verapamil co-administration, plasma concentrations rise progressively until they produce excessive RAAS suppression; management requires stopping verapamil and switching to a non-CYP3A4-inhibiting rate-control agent such as metoprolol
B) Verapamil competitively displaces aliskiren from plasma protein binding sites; as aliskiren's unbound fraction increases over three days, the free drug available for renal clearance initially increases but then saturates renal elimination capacity, causing net aliskiren accumulation and progressive hypotension; management requires reducing the aliskiren dose by 50% and continuing verapamil at the current dose
C) Aliskiren's oral bioavailability is limited primarily by P-gp-mediated efflux in the intestinal wall; verapamil inhibits intestinal P-gp, increasing the fraction of aliskiren absorbed with each dose; over three days of twice-daily verapamil dosing, plasma aliskiren concentrations rise progressively as each dose is absorbed more completely than the last until a new, substantially higher steady state is approached; the increased aliskiren exposure produces greater RAAS suppression and excessive blood pressure lowering; management requires holding aliskiren, allowing blood pressure to recover, and restarting at a reduced dose when verapamil is continued, or switching verapamil to a non-P-gp-inhibiting rate-control agent
D) Verapamil's calcium channel blockade in the renal afferent arteriole reduces renal blood flow and glomerular filtration rate, impairing aliskiren's minimal renal excretion; over three days aliskiren accumulates to toxic plasma concentrations despite its predominantly hepatobiliary elimination because even small reductions in renal clearance of a drug with 2.6% bioavailability produce disproportionate accumulation; management requires stopping aliskiren entirely as it is contraindicated with any agent that reduces renal blood flow
E) The interaction is pharmacodynamic rather than pharmacokinetic: verapamil and aliskiren both reduce systemic vascular resistance through independent mechanisms (L-type calcium channel blockade and RAAS suppression respectively), and the combined vasodilatory effect is simply additive; the three-day delay reflects the time required for verapamil to reach steady-state plasma concentrations at which its vasodilatory effect is maximal; no dose adjustment of aliskiren is needed — verapamil dose reduction is the appropriate response
ANSWER: C
Rationale:
Aliskiren's oral bioavailability of approximately 2.6% is primarily limited by P-glycoprotein (P-gp, ABCB1/MDR1)-mediated active efflux in the intestinal wall — absorbed aliskiren molecules are actively transported back into the intestinal lumen by P-gp before reaching the portal circulation; verapamil is a recognized P-gp inhibitor that reduces P-gp transport activity in intestinal epithelial cells; when verapamil is co-administered, the P-gp-mediated efflux of aliskiren from intestinal cells is reduced, allowing a substantially greater fraction of each oral aliskiren dose to reach the systemic circulation; the three-day delay before symptomatic hypotension reflects the pharmacokinetic time course of accumulation — aliskiren requires several days of co-administration with a P-gp inhibitor for plasma concentrations to rise from baseline to the new, higher steady state determined by reduced efflux, as each dose is absorbed more completely than at baseline; this is not an immediate interaction but a progressive accumulation driven by repeated oral dosing with enhanced absorption; the increased aliskiren plasma concentrations produce greater renin inhibition and more complete RAAS suppression, leading to excessive blood pressure lowering; management requires holding aliskiren to allow blood pressure recovery, and then either restarting aliskiren at a reduced dose appropriate for the higher bioavailability achieved in the presence of verapamil, or switching verapamil to a non-P-gp-inhibiting rate-control agent (such as beta-blockers like metoprolol or digoxin at appropriate doses) and restarting aliskiren at the original dose.
Option A: Option A is incorrect because while aliskiren is a minor CYP3A4 substrate, the dominant pharmacokinetic barrier to aliskiren absorption is P-gp-mediated intestinal efflux, not CYP3A4-mediated hepatic first-pass metabolism; verapamil's clinically significant interaction with aliskiren operates through P-gp inhibition increasing intestinal absorption, not primarily through CYP3A4 inhibition reducing hepatic clearance; furthermore, aliskiren is predominantly eliminated via the hepatobiliary route as largely unchanged drug, not by CYP3A4-dependent hepatic metabolism.
Option B: Option B is incorrect because aliskiren has low plasma protein binding (not high protein binding that would make competitive displacement pharmacokinetically significant); competitive displacement from plasma proteins is not the mechanism of the verapamil-aliskiren interaction; the interaction operates through P-gp inhibition at the intestinal wall level, not through protein binding competition in plasma.
Option D: Option D is incorrect because verapamil's calcium channel blockade in renal afferent arterioles does not meaningfully reduce aliskiren's elimination — aliskiren is predominantly eliminated via the hepatobiliary route with only approximately 1–2% of the dose recovered in urine; small reductions in the already-minimal renal excretion of aliskiren would not produce clinically significant accumulation; the mechanism is P-gp inhibition increasing intestinal absorption, not impaired renal clearance.
Option E: Option E is incorrect because while there is an additive pharmacodynamic component to the hypotension (verapamil does reduce blood pressure through calcium channel blockade), the primary driver of the progressive and severe hypotension three days after verapamil initiation is the pharmacokinetic increase in aliskiren plasma concentrations from P-gp inhibition; verapamil reaches steady state in approximately 1–2 days, not three days, and a pure pharmacodynamic additive effect would be expected to plateau at steady state rather than producing the progressive accumulation pattern observed; the interaction is primarily pharmacokinetic.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.